Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELN584103
- Development stage
- Unknown
- Lead developer
- Perrigo
- Modality
- Small Molecules
01
Overview
ELN584103 is a small-molecule research compound described chemically as 4-fluoro-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide and appears in internal intellectual property and contribution agreements between Elan group entities and Prothena/Neotope as one of multiple early-stage assets and materials transferred for neuroscience-related research.[1][7] Public documents identify its chemical structure but do not disclose a therapeutic target, mechanism of action, indication, or stage of clinical development, indicating that ELN584103 is an undisclosed preclinical tool or lead compound rather than an advanced drug candidate.[1][7]
- Other names
- 4-fluoro-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide
Beyond the preview
Go deeper on ELN584103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELN584103.